License Agreements (Additional Information) (Details)	1 Months Ended			3 Months Ended
	Jan. 31, 2023 USD ($)	May 31, 2012 USD ($)	Mar. 31, 2011 USD ($)	Mar. 31, 2023 USD ($) Milestone	Dec. 31, 2022 USD ($)
GFB Agreement [Member]
Business Acquisition [Line Items]
Upfront payment	$ 15,000,000.0			$ 15,000,000.0
Maximum future payments under license agreement	520,000,000.0
Development Milestone Payments	110,000,000.0
Regulatory Milestone Payments	150,000,000.0
Commercial sales milestones	$ 260,000,000.0
GFB Agreement [Member] | Maximum [Member]
Business Acquisition [Line Items]
Royalties paid, percentage	35.00%
GFB Agreement [Member] | Minimum [Member]
Business Acquisition [Line Items]
Royalties paid, percentage	25.00%
Intellectual Property License Agreement | Eli Lilly and Company
Business Acquisition [Line Items]
Upfront payment		$ 100,000
Royalty expiration term		6 years
License agreement term				15 years
Number of milestones reached | Milestone				0
Milestone payments				$ 0
Intellectual Property License Agreement | Eli Lilly and Company | Maximum [Member]
Business Acquisition [Line Items]
Contingent milestone payments payable		$ 16,000,000.0
Commercial milestone payments payable		$ 54,000,000.0
Patent License | PureTech Health
Business Acquisition [Line Items]
Contingent milestone payments payable			$ 10,000,000.0
Development and regulatory milestone payments under license agreement				8,000,000.0
Due to Related Parties				$ 0	$ 0
Patent License | PureTech Health | Maximum [Member]
Business Acquisition [Line Items]
Percentage of royalties payable on income from sublicensee, excluding royalties			25.00%
Patent License | PureTech Health | Minimum [Member]
Business Acquisition [Line Items]
Percentage of royalties payable on income from sublicensee, excluding royalties			15.00%